Last $24.97 USD
Change Today +0.37 / 1.50%
Volume 41.1K
HPTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Open
$24.43
Previous Close
$24.60
Day High
$25.39
Day Low
$24.21
52 Week High
02/28/14 - $32.98
52 Week Low
06/6/13 - $15.92
Market Cap
503.9M
Average Volume 10 Days
87.3K
EPS TTM
$-0.79
Shares Outstanding
20.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERION THERAPEUTICS INC (HPTX)

Related News

No related news articles were found.

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

54 Employees
Last Reported Date: 03/7/14
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $341.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $402.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $301.4K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $369.9K
Compensation as of Fiscal Year 2012.

hyperion therapeutics inc (HPTX) Key Developments

Hyperion Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 10:00 AM

Hyperion Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 10:00 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Donald J. Santel, Chief Executive Officer, President and Director.

Hyperion Therapeutics, Inc. Announces the Resignation of David Gryska from Board of Directors, Effective March 15, 2014

On March 5, 2014, Mr. David Gryska provided notification of his resignation from the Hyperion Therapeutics, Inc.’s Board of Directors effective as of March 15, 2014.

Hyperion Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for 2014

Hyperion Therapeutics, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net product revenue of $18,627,000. Income from operations was $879,000 against loss from operations of $7,795,000 a year ago. Income before income taxes was $517,000 against loss before income taxes of $8,285,000 a year ago. Net income attributable to common stockholders was $468,000 or $0.02 per diluted share against net loss attributable to common stockholders of $8,285,000 or $0.50 per diluted share a year ago. Adjusted net income was $4,067,000 or $0.19 per diluted share against adjusted net loss of $7,902,000 or $0.48 per diluted share a year ago. For the full year, the company reported net product revenue of $42,204,000. Loss from operations was $13,417,000 against $28,533,000 a year ago. Income before income taxes was $16,627,000 against loss before income taxes of $32,263,000 a year ago. Income before income taxes was $517,000 against loss before income taxes of $8,285,000 a year ago. Net income attributable to common stockholders was $16,627,000 or $0.80 per diluted share against net loss attributable to common stockholders of $32,263,000 or $4.45 per diluted share a year ago. Adjusted net loss was $5,463,000 or $0.28 per diluted share against adjusted net loss of $31,270,000 or $4.31 per diluted share a year ago. For 2014, Hyperion anticipates its adjusted operating expenses to be in the range of $52 million to $64 million which excludes amortization of the BUPHENYL intangible asset and stock-based compensation. The company expects amortization expense and stock-based compensation expense to be approximately $4 million to $5 million and $7.5 million to $8.5 million, respectively.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $24.97 USD +0.37

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies
 

Industry Analysis

HPTX

Industry Average

Valuation HPTX Industry Range
Price/Earnings 30.7x
Price/Sales 11.7x
Price/Book 4.1x
Price/Cash Flow 25.2x
TEV/Sales 9.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit www.hyperiontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.